News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter

Rinat Neuroscience Adds Chief Business Officer And Vice President, Clinical Development

10/19/2005 5:10:52 PM

PALO ALTO, Calif.--(BUSINESS WIRE)--April 13, 2004--Rinat Neuroscience Corporation, a developer of protein-based drugs for the treatment of diseases and disorders of the nervous system, today announced the appointment of two senior executives to the company's management team. David W. Pritchard has joined the company as chief business officer with responsibility for business development and finance. Patricia Ann Walicke, M.D., Ph.D. has been appointed vice president, clinical development.

"David Pritchard joins Rinat with over 25 years of experience in general management, business development and financial management within the biotechnology and pharmaceutical industry," said Ron Eastman, chief executive officer of Rinat. "His extensive experience in corporate partnering and finance, including the negotiation of major corporate partnerships and executing of financings, will serve Rinat well as we seek to realize the value of our product portfolio and grow the company.

Mr. Eastman continued, "Similarly, Patricia Walicke has considerable clinical and regulatory expertise in the development of protein-based therapeutics earned at one of the biotechnology industry's premier companies. Moreover, she has a strong background in neurobiology, with extensive experience gained in both industry and academia. I am very pleased to welcome these two experienced executives to the Rinat management team."

David W. Pritchard

David Pritchard's experience spans all phases of product development and commercialization from startup through clinical development to the marketplace. Most recently, he was senior vice president and chief financial officer at Matrix Pharmaceuticals and managed that company's sale to Chiron Corporation in 2002. Prior to that he served as vice president of business development and finance, and chief financial officer of Metabolex, Inc. from 1992 to 2000, where he negotiated four major worldwide corporate alliances with major pharmaceutical companies and completed four successful rounds of financing. Mr. Pritchard began his biotechnology industry career at Triton Biosciences, Inc. from 1984 to 1992, as one of the company's founding managers, and successfully managed the sale of Triton's businesses in several parts to Schering A.G., CIBA-Geigy, Bayer and Schering Plough for over $400 million. He holds an MBA degree from Stanford University, and a B.S. in Chemical Engineering from Cornell.

Patricia Ann Walicke, M.D., Ph.D.

Dr. Walicke joins Rinat from Genentech, Inc., where she was a medical director in that company's department of clinical affairs. There she oversaw the clinical development of Raptiva(TM), that company's monoclonal antibody therapeutic for psoriasis. Prior to joining Genentech, she served as director, clinical and regulatory affairs at Athena Neurosciences, Inc. (now part of Elan Corporation). There she directed clinical development for the company's experimental monoclonal antibody product for multiple sclerosis, Antegren(TM). She also previously served as director, medical and scientific services at Quintiles Pacific, Inc., where she participated in clinical trials involving Alzheimer's disease, migraine, multiple sclerosis, stroke and epilepsy in Phases I to IV. Dr. Walicke has also had a distinguished academic career in the field of neurology, most recently serving as an adjunct assistant professor in the Department of Neurology at the University of California, San Francisco. She received her B.S. degree from the Massachusetts Institute of Technology, her M.D. degree from Harvard Medical School and her Ph.D. in neurobiology from Harvard University.

About Rinat Neuroscience Corporation

Rinat Neuroscience Corporation, based in Palo Alto, California, was founded in 2001 when Genentech, Inc. (NYSE: DNA), a leader in the development of therapeutic proteins, spun out its key neuroscience assets under a broad license to Rinat. Genentech invested significant resources in support of these assets over 15 years, and Rinat is now building on them as the pioneer in developing and commercializing protein-based therapeutics for the treatment of diseases and disorders of the nervous system. Rinat anticipates filing its first IND in the second quarter of 2004 for acute and chronic pain. For more information on Rinat, please visit or contact Beth Calvin at 650-213-5304.


Rinat Neuroscience Corp. Beth Calvin, 650-213-5304 or

Kureczka/Martin Associates Joan Kureczka, 415-821-2413

Read at

comments powered by Disqus